Terrence P. Cescon

2.6k total citations
18 papers, 332 citations indexed

About

Terrence P. Cescon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Terrence P. Cescon has authored 18 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Terrence P. Cescon's work include Colorectal Cancer Treatments and Studies (5 papers), BRCA gene mutations in cancer (4 papers) and Cancer Treatment and Pharmacology (4 papers). Terrence P. Cescon is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), BRCA gene mutations in cancer (4 papers) and Cancer Treatment and Pharmacology (4 papers). Terrence P. Cescon collaborates with scholars based in United States, Mexico and Canada. Terrence P. Cescon's co-authors include John Malick, Susan Montgomery, Karen Ruth, Brian L. Egleston, Ruth Bingler, Mary B. Daly, Andrea M. Barsevick, Suzanne M. Miller, Bobby L. Clark and Charles E. Geyer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Terrence P. Cescon

18 papers receiving 329 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Terrence P. Cescon United States 10 175 115 84 77 53 18 332
Ingrid Slade United Kingdom 9 106 0.6× 238 2.1× 34 0.4× 22 0.3× 132 2.5× 10 431
Edibaldo Silva United States 8 50 0.3× 69 0.6× 75 0.9× 46 0.6× 54 1.0× 16 254
Isabelle Himsl Germany 8 103 0.6× 50 0.4× 78 0.9× 41 0.5× 81 1.5× 14 363
Érika Maria Monteiro Santos Brazil 14 200 1.1× 174 1.5× 240 2.9× 44 0.6× 140 2.6× 33 506
Muriel A. Adank Netherlands 12 111 0.6× 321 2.8× 84 1.0× 43 0.6× 136 2.6× 32 584
R.A.E.M. Tollenaar Netherlands 11 165 0.9× 58 0.5× 59 0.7× 59 0.8× 79 1.5× 22 347
Edgard Nassif Canada 10 101 0.6× 77 0.7× 57 0.7× 85 1.1× 66 1.2× 18 336
Kate Ingarfield United Kingdom 9 197 1.1× 27 0.2× 30 0.4× 152 2.0× 133 2.5× 17 550
Sabine Grill Germany 9 83 0.5× 79 0.7× 11 0.1× 18 0.2× 48 0.9× 22 259
Yassir Sbitti Morocco 10 125 0.7× 81 0.7× 52 0.6× 57 0.7× 83 1.6× 31 295

Countries citing papers authored by Terrence P. Cescon

Since Specialization
Citations

This map shows the geographic impact of Terrence P. Cescon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terrence P. Cescon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terrence P. Cescon more than expected).

Fields of papers citing papers by Terrence P. Cescon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terrence P. Cescon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terrence P. Cescon. The network helps show where Terrence P. Cescon may publish in the future.

Co-authorship network of co-authors of Terrence P. Cescon

This figure shows the co-authorship network connecting the top 25 collaborators of Terrence P. Cescon. A scholar is included among the top collaborators of Terrence P. Cescon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terrence P. Cescon. Terrence P. Cescon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Batchelor, Tracy T., Minhee Won, Arnab Chakravarti, et al.. (2023). NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neuro-Oncology Advances. 5(1). vdad116–vdad116. 7 indexed citations
2.
3.
Abu‐Khalaf, Maysa, Chun Wang, Zhenchao Zhang, et al.. (2022). Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. Cancers. 14(12). 2872–2872. 3 indexed citations
4.
Evens, Andrew M., Fangxin Hong, Thomas M. Habermann, et al.. (2020). A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical Cancer Research. 26(17). 4468–4477. 16 indexed citations
5.
Chávarri-Guerra, Yanin, Carolyn B. Hendricks, Terrence P. Cescon, et al.. (2020). Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer. Journal of Geriatric Oncology. 12(5). 749–751. 8 indexed citations
6.
Weitzel, Jeffrey N., Kathleen R. Blazer, Thomas P. Slavin, et al.. (2019). Germline mutation profile among Hispanic women with epithelial ovarian cancer (EOC).. Journal of Clinical Oncology. 37(15_suppl). 1584–1584. 1 indexed citations
7.
8.
9.
Konski, André, Joshua E. Meyer, Michael C. Joiner, et al.. (2014). Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology. 113(1). 35–40. 11 indexed citations
10.
Montgomery, Susan, Andrea M. Barsevick, Brian L. Egleston, et al.. (2013). Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial. Familial Cancer. 12(3). 537–546. 74 indexed citations
11.
Infante, Jeffrey R., Tony R. Reid, Allen Lee Cohn, et al.. (2013). Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study. Cancer. 119(14). 2555–2563. 38 indexed citations
12.
Infante, Jeffrey R., Allen Lee Cohn, T. Reid, et al.. (2011). A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(4_suppl). 485–485. 17 indexed citations
13.
Hainsworth, John D., David R. Spigel, Bobby L. Clark, et al.. (2010). Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site. The Cancer Journal. 16(1). 70–75. 46 indexed citations
14.
Barsevick, Andrea M., Susan Montgomery, Karen Ruth, et al.. (2008). Intention to communicate BRCA1/BRCA2 genetic test results to the family.. Journal of Family Psychology. 22(2). 303–312. 39 indexed citations
15.
Jacobs, Samuel A., John Wilson, Janell Seeger, et al.. (2007). A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Investigational New Drugs. 25(6). 545–551. 17 indexed citations
16.
Giri, Veda N., Jennifer Beebe‐Dimmer, André Konski, et al.. (2007). Prostate Cancer Risk Assessment Program: A 10-Year Update of Cancer Detection. The Journal of Urology. 178(5). 1920–1924. 25 indexed citations
17.
Jacobs, Samuel A., J. A. Wilson, Janell Seeger, et al.. (2007). A phase II clinical trial of ZD1839 (gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1059–1059. 1 indexed citations
18.
Atkins, James N., Samuel A. Jacobs, H. Samuel Wieand, et al.. (2005). Pemetrexed/Oxaliplatin for First-Line Treatment of Patients with Advanced Colorectal Cancer: A Phase II Trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clinical Colorectal Cancer. 5(3). 181–187. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ingrid Slade Breakdown of academic impact, for papers by Edibaldo Silva Breakdown of academic impact, for papers by Isabelle Himsl Breakdown of academic impact, for papers by Érika Maria Monteiro Santos Breakdown of academic impact, for papers by Muriel A. Adank Breakdown of academic impact, for papers by R.A.E.M. Tollenaar Breakdown of academic impact, for papers by Edgard Nassif Breakdown of academic impact, for papers by Kate Ingarfield Breakdown of academic impact, for papers by Sabine Grill Breakdown of academic impact, for papers by Yassir Sbitti
Rankless by CCL
2026